abstract details

The summaries are free for public use. ARTHROS will continue to add and archive summaries of articles deemed relevant to ARTHROS by our Faculty.

Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases


Mayence A1, Vanden Eynde JJ2. Pharmaceuticals (Basel). 2019 Mar 12;12(1). pii: E37. doi: 10.3390/ph12010037.

Author Information

1 Haute Ecole Provinciale de Hainaut-Condorcet, 7330 Saint-Ghislain, Belgium. annie.mayence@alumini.umons.ac.be.

2 Formerly head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium. jean-jacques.vandeneynde@ex.umons.ac.be.


In 2018, Baricitinib was approved by the Food and Drig Administration (FDA) for the treatment of rheumatoid arthritis. Baricitinib exerts its action by targeting Janus kinases (JAK). In this study, we describe the necessary steps for preparing the drug using two alternative routes.